Full-Time

Senior Manager

R&D Data Steward

Posted on 11/23/2025

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$137.6k - $182.6k/yr

Remote in USA

Remote

Category
Data & Analytics (1)
Required Skills
Databricks
Requirements
  • Bachelor’s degree in Life Sciences, Information Systems, Data Management, or related field; advanced degree preferred.
  • 7+ years of experience in data stewardship, governance, or data management, with strong exposure to Pharma R&D data.
  • Proven ability to manage and mentor data stewardship teams.
  • Deep understanding of Pharma R&D data domains, regulatory requirements, and data standards.
  • Hands-on experience with stewardship and metadata platforms (e.g., Informatica CDGC/CDQ for cataloging and business metadata, Collibra, Reltio, Databricks).
  • Strong problem-solving and stakeholder management skills with ability to balance scientific, operational, and compliance needs.
  • Excellent written and verbal communication skills; ability to present stewardship and metadata value to leadership.
  • Demonstrated commitment to building a culture of data trust, quality, and contextual understanding.
Responsibilities
  • Mentor a team of data stewards assigned to support multiple R&D domains.
  • Define stewardship roles, workflows, and accountabilities to ensure clear ownership of data entities, business metadata, and processes.
  • Act as escalation point for complex data issues, ensuring timely resolution and alignment with governance policies.
  • Operationalize data governance policies, standards, and SOPs in partnership with the governance team.
  • Define, maintain, and curate business metadata (e.g., data definitions, glossary terms, business rules, usage context) within data catalog.
  • Ensure consistency of business metadata across domains to avoid duplication, misinterpretation, or misalignment.
  • Monitor and enforce data quality, completeness, and accuracy across operational systems and data products.
  • Ensure data and metadata are managed in compliance with internal and external standards.
  • Define and track domain-specific data quality metrics; coordinate remediation with data engineering and business partners.
  • Maintain metadata-driven data quality rules to ensure trusted data for downstream consumption.
  • Establish root-cause analysis and preventive action processes to reduce recurring data issues.
  • Drive continuous improvement of stewardship workflows through automation and AI/GenAI tools (e.g., automated metadata tagging, anomaly detection).
  • Serve as the key stewardship liaison for functional partners (Clinical Ops, Safety, Regulatory, Portfolio, Research).
  • Collaborate with data product teams to ensure domain data and business metadata are curated, contextualized, and analytics-ready.
  • Partner with governance and enablement leads to align stewardship with enterprise data architecture, data catalog, data quality and data marketplace capabilities.
  • Build training, guidance, and support materials to enable business users to understand and leverage governed data.
  • Drive awareness and adoption of stewardship and metadata practices through forums, knowledge-sharing, and communities of practice.
  • Champion a data-driven culture by highlighting the value of trusted data and contextual business metadata in enabling insights and compliance.
  • Track stewardship performance (e.g., data quality improvement, metadata coverage, issue resolution turnaround, compliance readiness).
  • Report stewardship value delivered such as time saved, reduction of manual rework, and risk avoidance enabled by data governance.
  • Provide transparent reporting to governance councils and leadership on stewardship, adoption, and impact.
Desired Qualifications
  • Advanced degree in Life Sciences, Information Systems, Data Management, or related field.
  • Experience with data stewardship, governance, or data management in Pharma R&D data domains.
  • Hands-on experience with Informatica Cloud Data Governance and Catalog (CDGC/CDQ) for cataloging and business metadata, Collibra, Reltio, Databricks.
  • Experience mentoring data stewardship teams.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE